person · Reporting owner

Morris Arlene

Disclosed activity across 6 companies

Tapewire entity: 18365
SEC CIK: 0001362520

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cogent Biosciences, Inc.COGT · Entity 3793	Director	August 27, 2026	August 31, 2026
Edgewise Therapeutics, Inc.EWTX · Entity 3965	Director	June 05, 2026	June 17, 2026
PALATIN TECHNOLOGIES INCPTN · Entity 7649	Director	August 03, 2026	August 05, 2026
VIVEVE MEDICAL, INC.VIVE · Entity 11899	Director	January 03, 2023	January 05, 2023
Viridian Therapeutics, Inc.\DEVRDN · Entity 4316	Director	July 01, 2026	July 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cogent Biosciences, Inc.

Report date August 27, 2026 · Filed August 31, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-08-27 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-08-27 · Exercise / conversion · Acquired 41,927 · Balance 41,927 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. Row 2 · 2026-08-27 · Exercise / conversion · Acquired 3,583 · Balance 45,510 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. Row 3 · 2026-08-27 · Sale · Disposed 42,349 · Balance 3,161 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 4 · 2026-08-27 · Sale · Disposed 3,161 · Balance 0 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.64 · Expires 2035-06-04	Direct	2,773	Reported balance After 2026-08-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-27 · Exercise / conversion · Disposed 41,927 · Balance 2,773 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F4: These options are fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2030-06-09	Direct	0	Reported balance After 2026-08-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-27 · Exercise / conversion · Disposed 3,583 · Balance 0 F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F4: These options are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.

F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F4: These options are fully vested.

Edgewise Therapeutics, Inc.

Report date June 05, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05	Direct	16,377	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

PALATIN TECHNOLOGIES INC

Report date August 03, 2026 · Filed August 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.70 · Expires 2037-08-03	Direct	3,497	Reported balance After 2026-08-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-03 · Other · Acquired 2,400 · Balance 3,497 F1: Stock Option granted under the 2011 Stock Incentive Plan as amended. The option vests as to 50% on August 3, 2027 and as to the remaining 50% on August 3, 2028. The option was granted by the Compensation Committee on August 3, 2026, and there was no impediment to the grant of option.

Filing footnotes · ownership attribution and instrument terms

F1: Stock Option granted under the 2011 Stock Incentive Plan as amended. The option vests as to 50% on August 3, 2027 and as to the remaining 50% on August 3, 2028. The option was granted by the Compensation Committee on August 3, 2026, and there was no impediment to the grant of option.

VIVEVE MEDICAL, INC.

Report date January 03, 2023 · Filed January 05, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	36,000	Reported balance After 2023-01-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-03 · Grant · Acquired 36,000 · Balance 36,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.

F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer.

Viridian Therapeutics, Inc.\DE

Report date July 01, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01	Direct	32,341	Reported balance After 2026-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dimension Therapeutics, Inc.

Report date November 07, 2017 · Filed November 07, 2017

Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2025-08-11	Direct	Reported balance After 2017-11-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-11-07 · Disposition to issuer · Disposed 44,474 · Balance 0 F1: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-05-18	Direct	Reported balance After 2017-11-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-11-07 · Disposition to issuer · Disposed 32,069 · Balance 0 F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2027-05-24	Direct	Reported balance After 2017-11-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-11-07 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.

F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 27, 2026 Filed Aug 31, 2026 21:01 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	Exercise / conversionStock Option (Right to Buy) · Derivative	3,583	$0.00 Strike: $2.52	$0.00	Disclosure SEC source: 0001193125-26-377001 · ownership.xml · derivative · entry 6 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,583 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	Exercise / conversionStock Option (Right to Buy) · Derivative	41,927	$0.00 Strike: $5.64	$0.00	Disclosure SEC source: 0001193125-26-377001 · ownership.xml · derivative · entry 5 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,773 Underlying: Common Stock · 41,927 shares Expires 2035-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	SaleCommon Stock	3,161	$37.54	$118,662.68	Disclosure SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 4 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	SaleCommon Stock	42,349	$37.09	$1,570,830.28	Disclosure SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 3 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,161 F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	Exercise / conversionCommon Stock	3,583	$2.52	$9,029.16	Disclosure SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	Exercise / conversionCommon Stock	41,927	$5.64	$236,468.28	Disclosure SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026. Read SEC document
August 03, 2026 Filed Aug 5, 2026 20:30 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	OtherStock Option (Right to Buy) · Derivative	2,400	$0.00 Strike: $7.70	$0.00	Disclosure SEC source: 0001493152-26-036187 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,497 Underlying: Common Stock · 2,400 shares Expires 2037-08-03 F1 · derivative.exercise_date: Stock Option granted under the 2011 Stock Incentive Plan as amended. The option vests as to 50% on August 3, 2027 and as to the remaining 50% on August 3, 2028. The option was granted by the Compensation Committee on August 3, 2026, and there was no impediment to the grant of option. Read SEC document
July 01, 2026 Filed Jul 2, 2026 20:15 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantStock Option (Right to Buy) · Derivative	32,341	$0.00 Strike: $18.48	$0.00	Disclosure SEC source: 0001193125-26-294546 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,341 Underlying: Common Stock · 32,341 shares Expires 2036-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:30 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	GrantStock Option (Right to Buy) · Derivative	17,901	$0.00 Strike: $31.98	$0.00	Disclosure SEC source: 0001193125-26-267667 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2036-06-09 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document
June 05, 2026 Filed Jun 17, 2026 20:46 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	16,377	$0.00 Strike: $35.59	$0.00	Disclosure SEC source: 0001362520-26-000001 · primarydocument.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document
December 09, 2025 Filed Dec 11, 2025 22:00 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (Right to Buy) · Derivative	2,400	$0.00 Strike: $21.38	$0.00	Disclosure SEC source: 0001493152-25-027271 · ownership.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,927 Underlying: Common Stock · 2,400 shares Expires 2035-12-09 F2 · derivative.exercise_date: Stock Options granted under the 2011 Stock Incentive Plan, the option vests as to 50% on December 9, 2026 and as to the remaining 50% on December 9, 2027. The options were granted by the Compensation Committee on December 9, 2025, and there were no impediments to the grant of options. Read SEC document
December 09, 2025 Filed Dec 11, 2025 22:00 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (Right to Buy) · Derivative	2,400	$0.00 Strike: $21.38	$0.00	Disclosure SEC source: 0001493152-25-027271 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,527 Underlying: Common Stock · 2,400 shares Expires 2035-12-09 F1 · derivative.exercise_date: Stock Options granted under the 2011 Stock Incentive Plan, the option vests on December 9, 2026, and in the event that the director does not serve until December 31, 2026, is prorated based on the period of service at the rate of 1/12 per month on the last day of each month, starting on January 31, 2026. The options were granted by the Compensation Committee on December 9, 2025, and there were no impediments to the grant of options. Read SEC document
July 01, 2025 Filed Jul 2, 2025 20:45 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $14.47	$0.00	Disclosure SEC source: 0000950170-25-093107 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Read SEC document
June 16, 2025 Filed Jun 18, 2025 23:36 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $14.68	$0.00	Disclosure SEC source: 0001562180-25-004958 · primarydocument.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders. Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:17 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	GrantStock Option (Right to Buy) · Derivative	44,700	$0.00 Strike: $5.64	$0.00	Disclosure SEC source: 0000950170-25-082348 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,700 Underlying: Common Stock · 44,700 shares Expires 2035-06-04 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders. Read SEC document
July 15, 2024 Filed Jul 16, 2024 20:31 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	12,000	$0.00	$0.00	Disclosure SEC source: 0001654954-24-008998 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,580 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 4, 2025. The restricted share units were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 4, 2025. The restricted share units were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024. Read SEC document
June 26, 2024 Filed Jun 28, 2024 20:05 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $12.31	$0.00	Disclosure SEC source: 0000950170-24-079038 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2034-06-26 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board. Read SEC document
June 10, 2024 Filed Jun 12, 2024 23:26 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	20,594	$0.00 Strike: $17.13	$0.00	Disclosure SEC source: 0001562180-24-005020 · primarydocument.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,594 Underlying: Common Stock · 20,594 shares Expires 2034-06-10 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 10, 2024 will become vested on the earlier of (i) June 10, 2025 or (ii) the business day prior to the 2025 annual meeting of stockholders. Read SEC document
June 05, 2024 Filed Jun 13, 2024 23:06 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	GrantStock Option (Right to Buy) · Derivative	44,700	$0.00 Strike: $8.92	$0.00	Disclosure SEC source: 0000950170-24-073226 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,700 Underlying: Common Stock · 44,700 shares Expires 2034-06-05 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders. Read SEC document
May 06, 2024 Filed May 7, 2024 23:52 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Options (Right to buy) · Derivative	34,311	$0.00 Strike: $20.34	$0.00	Disclosure SEC source: 0001562180-24-003899 · primarydocument.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,311 Underlying: Common Stock · 34,311 shares Expires 2034-05-06 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest each month beginning on June 6, 2024, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document
July 15, 2023 Filed Jul 16, 2024 20:31 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $1.83	$0.00	Disclosure SEC source: 0001654954-24-008998 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,180 Underlying: Common Stock · 17,000 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests on June 4, 2025, and in the event that the director does not serve until June 30, 2025, is prorated based on the period of service at the rate of 1/12 per month on the last day of each month, starting on July 31, 2024. The options were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024. Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:00 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $2.19	$0.00	Disclosure SEC source: 0001654954-23-008307 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-20 F2 · derivative.exercise_date: The option vests on June 30, 2024, and in the event that the director does not serve until June 30, 2024, is prorated based on the period of service at the rate of 1/12 per month on the last day of each month, starting on July 31, 2023. Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:00 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001654954-23-008307 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,093 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 20, 2024. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 20, 2024. Read SEC document
June 14, 2023 Filed Jun 16, 2023 23:51 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $27.67	$0.00	Disclosure SEC source: 0000950170-23-028721 · ownership.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document
June 07, 2023 Filed Jun 8, 2023 20:58 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	GrantStock Option (Right to Buy) · Derivative	36,700	$0.00 Strike: $11.70	$0.00	Disclosure SEC source: 0000899243-23-014905 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,700 Underlying: Common Stock · 36,700 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders. Read SEC document
January 03, 2023 Filed Jan 5, 2023 16:03 UTC	VIVEVE MEDICAL, INC. VIVE · Entity 11899	GrantRestricted Stock Unit · Derivative	36,000	$0.00	$0.00	Disclosure SEC source: 0001437749-23-000482 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. F2 · derivative.expiration_date: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:31 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (Right to Buy) · Derivative	128,000	$0.00 Strike: $0.29	$0.00	Disclosure SEC source: 0001654954-22-008783 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 128,000 shares Expires 2032-06-22 F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2022. Read SEC document
June 22, 2022 Filed Jun 24, 2022 23:31 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	73,000	$0.00	$0.00	Disclosure SEC source: 0001654954-22-008783 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,667 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023. Read SEC document
June 08, 2022 Filed Jun 10, 2022 11:30 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $12.31	$0.00	Disclosure SEC source: 0000899243-22-021801 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document
June 07, 2022 Filed Jun 9, 2022 21:10 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	GrantStock Option (Right to Buy) · Derivative	30,700	$0.00 Strike: $4.59	$0.00	Disclosure SEC source: 0000899243-22-021646 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2032-06-07 F1 · derivative.exercise_date: This annual stock option award was made on the date of the 2022 Annual Meeting of Stockholders pursuant to the company's Non-Employee Director Compensation Program and shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders. Read SEC document
January 04, 2022 Filed Jan 6, 2022 16:03 UTC	VIVEVE MEDICAL, INC. VIVE · Entity 11899	GrantNon-Qualified Stock Option (Right to Purchase) · Derivative	22,000	$0.00 Strike: $1.26	$0.00	Disclosure SEC source: 0001437749-22-000547 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan, as amended (the "2013 Plan") and received 22,000 non-qualified stock options on January 4, 2022 (the "Grant Date"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date. Read SEC document
July 01, 2021 Filed Jul 1, 2021 19:37 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon stock	33,000	$0.62	$20,460.00	Disclosure SEC source: 0001654954-21-007511 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,666 F1 · price: Weighted average of price paid per share on order, with prices per share ranging from $0.6149 to $0.6217. The reporting person hereby undertakes upon request to provide to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
July 01, 2021 Filed Jul 2, 2021 15:20 UTC Amendment	PALATIN TECHNOLOGIES INC PTN · Entity 7649	PurchaseCommon stock	33,000	$0.62	$20,460.00	Disclosure SEC source: 0001654954-21-007565 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,666 F1 · kind: Amended to reflect open market purchases of non-derivative security. F2 · price: Weighted average of price paid per share on order, with prices per share ranging from $0.6149 to $0.6217. The reporting person hereby undertakes upon request to provide to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 23, 2021 Filed Jun 25, 2021 16:06 UTC	VIVEVE MEDICAL, INC. VIVE · Entity 11899	GrantNon-Qualified Stock Option (Right to Purchase) · Derivative	51,700	$0.00 Strike: $2.73	$0.00	Disclosure SEC source: 0001437749-21-015657 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2031-06-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 51,700 non-qualified stock options on June 23, 2021 (the "Grant Date"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date. Read SEC document
June 22, 2021 Filed Jun 24, 2021 21:01 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock option (right to buy) · Derivative	128,000	$0.00 Strike: $0.55	$0.00	Disclosure SEC source: 0001654954-21-007256 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common stock · 128,000 shares Expires 2031-06-22 F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2021. Read SEC document
June 22, 2021 Filed Jun 24, 2021 21:01 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon stock	77,000	$0.00	$0.00	Disclosure SEC source: 0001654954-21-007256 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,666 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2022. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2022. Read SEC document
June 03, 2021 Filed Jun 16, 2021 22:27 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $16.60	$0.00	Disclosure SEC source: 0000899243-21-024221 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 3, 2022 or (ii) the Issuer's 2022 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document
March 11, 2021 Filed Mar 15, 2021 22:54 UTC	Cogent Biosciences, Inc. COGT · Entity 3793	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $8.45	$0.00	Disclosure SEC source: 0000899243-21-011688 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a three year period. Read SEC document
February 04, 2021 Filed Feb 8, 2021 22:38 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantDirector Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $20.50	$0.00	Disclosure SEC source: 0000899243-21-005204 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document
January 20, 2021 Filed Jan 22, 2021 19:17 UTC	VIVEVE MEDICAL, INC. VIVE · Entity 11899	GrantRestricted Stock Unit · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001437749-21-001111 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 25,000 RSUs on January 20, 2021 (the "Grant Date"). The RSUs vest in full on the second anniversary of the Grant Date. F2 · derivative.expiration_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 25,000 RSUs on January 20, 2021 (the "Grant Date"). The RSUs vest in full on the second anniversary of the Grant Date. Read SEC document
September 21, 2020 Filed Sep 22, 2020 11:04 UTC	VIVEVE MEDICAL, INC. VIVE · Entity 11899	GrantNon-Qualified Stock Option (Right to Purchase) · Derivative	165,000	$0.00 Strike: $0.54	$0.00	Disclosure SEC source: 0001437749-20-019987 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2030-09-20 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 165,000 non-qualified stock options on September 21, 2020 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document
June 16, 2020 Filed Jun 18, 2020 21:01 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (Right to Buy) · Derivative	127,000	$0.00 Strike: $0.58	$0.00	Disclosure SEC source: 0001654954-20-006787 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,000 Underlying: Common Stock · 127,000 shares Expires 2030-06-16 F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2020. Read SEC document
June 16, 2020 Filed Jun 18, 2020 21:01 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	73,000	$0.00	$0.00	Disclosure SEC source: 0001654954-20-006787 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,583 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 16, 2021. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 16, 2021. Read SEC document
June 09, 2020 Filed Jun 11, 2020 20:24 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	14,331	$0.00 Strike: $0.63	$0.00	Disclosure SEC source: 0001209191-20-035928 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,331 Underlying: Common Stock · 14,331 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
May 21, 2020 Filed May 22, 2020 21:18 UTC	Viridian Therapeutics, Inc.\DE MGEN · Entity 4316	GrantStock Option (right to buy) · Derivative	24,000	$0.00 Strike: $0.63	$0.00	Disclosure SEC source: 0001209191-20-031835 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document
November 26, 2019 Filed Nov 27, 2019 19:30 UTC	VIVEVE MEDICAL, INC. VIVE · Entity 11899	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	330,000	$0.00 Strike: $0.87	$0.00	Disclosure SEC source: 0001437749-19-023674 · rdgdoc.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2029-11-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document
July 26, 2019 Filed Jul 29, 2019 20:06 UTC	Cogent Biosciences, Inc. UMRX · Entity 3793	GrantStock Option (Right to Buy) · Derivative	28,661	$0.00 Strike: $2.05	$0.00	Disclosure SEC source: 0001209191-19-043470 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,661 Underlying: Common Stock · 28,661 shares Expires 2029-07-26 F1 · derivative.exercise_date: This stock option shall vest in 36 equal monthly installments; subject to continued service to the Issuer. Read SEC document
June 24, 2019 Filed Jun 26, 2019 20:38 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (right to buy) · Derivative	52,000	$0.00 Strike: $1.34	$0.00	Disclosure SEC source: 0001654954-19-007690 · section16.xml · derivative · entry 2 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2029-06-24 F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2019. Read SEC document
June 24, 2019 Filed Jun 26, 2019 20:38 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	32,000	$0.00	$0.00	Disclosure SEC source: 0001654954-19-007690 · section16.xml · nonDerivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,333 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 24, 2020. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 24, 2020. Read SEC document
June 19, 2019 Filed Jun 21, 2019 21:17 UTC	Viridian Therapeutics, Inc.\DE MGEN · Entity 4316	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $2.36	$0.00	Disclosure SEC source: 0001209191-19-038573 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.